Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04291729
Recruitment Status : Completed
First Posted : March 2, 2020
Last Update Posted : April 13, 2020
Sponsor:
Collaborator:
Ascletis Pharmaceuticals Co., Ltd.
Information provided by (Responsible Party):
The Ninth Hospital of Nanchang

Brief Summary:
Evaluation of the efficacy and safety of Ganovo combined with ritonavir for patients infected with SARS-CoV-2.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Ganovo+ritonavir+/-Interferon nebulization Phase 4

Detailed Description:
Given no specific antiviral therapies for new coronavirus pneumonia approved yet and Ganovo, an oral Hepatitis C virus protease inhibitor, approved in China in June 2018 , this open, controlled trial will evaluate the efficacy and safety of Ganovo in hospitalized patients infected with SARS-CoV-2.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection
Actual Study Start Date : February 17, 2020
Actual Primary Completion Date : March 19, 2020
Actual Study Completion Date : March 19, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Ganovo+ritonavir with or without interferon nebulization Drug: Ganovo+ritonavir+/-Interferon nebulization
Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.




Primary Outcome Measures :
  1. Rate of composite adverse outcomes [ Time Frame: 14 days ]
    Defined as SPO2≤ 93% without oxygen supplementation, PaO2/FiO2 ≤300mmHg or a respiratory rate ≥30 breaths per min without supplemental oxygen


Secondary Outcome Measures :
  1. Time to recovery [ Time Frame: 14 days ]
    Clinical recovery was defined as sustained (48 hours) alleviation of illness based on symptom scores (fever, cough, diarrhea, myalgia, dyspnea) all being absent and no evidence for progression (newly-presented dyspnea, SpO2 decline ≥3%, respiratory rate ≥ 24 breaths per min without supplemental oxygen).

  2. Rate of no fever [ Time Frame: 14 days ]
    Rate of no fever

  3. Rate of no cough [ Time Frame: 14 days ]
    Rate of no cough

  4. Rate of no dyspnea [ Time Frame: 14 days ]
    Rate of no dyspnea

  5. Rate of no requiring supplemental oxygen [ Time Frame: 14 days ]
    Rate of no requiring supplemental oxygen

  6. Rate of undetectable New coronavirus pathogen nucleic acid [ Time Frame: 14 days ]
    Rate of undetectable New coronavirus pathogen nucleic acid

  7. Rate of mechanical ventilation [ Time Frame: 14 days ]
    Rate of mechanical ventilation

  8. Rate of ICU admission [ Time Frame: 14 days ]
    Rate of ICU admission

  9. Rate of serious adverse event [ Time Frame: 14 days ]
    Rate of serious adverse event



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 18-75 years old;
  • Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (Current Trial Version);
  • Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days);
  • Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;
  • Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration;
  • Patients who voluntarily sign informed consent.

Exclusion Criteria:

  • The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR >= 30 times / min; or SaO2 / SpO2 <93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) <300MMHG (1mmhg = 0.133kpa);
  • Pneumonia patients with severe new coronavirus infection meet one of the following conditions: respiratory failure and need mechanical ventilation; or shock; or other organ failure combined with ICU monitoring treatment;
  • Severe liver disease (such as child Pugh score >=C, AST > 5 times upper limit);
  • Patients with contraindications specified in the instructions of ritonavir tablets;
  • The pregnancy test of female subjects in the screening period was positive;
  • The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04291729


Locations
Layout table for location information
China, Jiangxi
The Ninth Hospital of Nanchang
Nanchang, Jiangxi, China, 330000
Sponsors and Collaborators
The Ninth Hospital of Nanchang
Ascletis Pharmaceuticals Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Yahong Chen, MD Ascletis Pharmaceuticals Co., Ltd.
Layout table for additonal information
Responsible Party: The Ninth Hospital of Nanchang
ClinicalTrials.gov Identifier: NCT04291729    
Other Study ID Numbers: ASC-CTP-NC-01
First Posted: March 2, 2020    Key Record Dates
Last Update Posted: April 13, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Interferons
Ritonavir
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors